ABSTRACT
MATERIALS
AND METHODS 
Test sera

Peptide
A 24-mer peptide Immunoblotting assay Membranes of rat atria were prepared as previously described (13) and subjected to electrophoresis on 8.5% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose sheets and revealed with different IgGs from chagasic or normal individuals as described (13 
Detection of antipeptide antibodies
The presence of antipeptide antibodies was demonstrated by an enzyme immunoassay using the 24-mer peptide as antigen. Figure  1 by the ability of the peptide (10 fold concentrated)
to inhibit the interaction (Fig. 1, right blotting experiments on rat cardiac membranes and tested the ability of antipeptide antibodies to recognize the whole receptor. Figure   2 shows that IgGs from chagasic, but not normal, patients recognize whole mAChRs similarly to a monoclonal antiM2-mAChR. As expected, antipeptide IgG also revealed bands of M2 mAChRs coincident with those labeled by the monoclonal or total chagasic IgG. Moreover, when 5 X iO M peptide was included in the reaction, antipeptide antibodies failed to label any band of receptor. On the other hand, the fraction of chagasic IgG lacking antipeptide antibodies eluted from the affinity column showed a different pattern of recognition.
Some bands at high molecular weights could correspond to other heart proteins recognized by additional antibodies, as has been reported elsewhere (6, 7, 25) . In contrast, the bands labeled by antipeptide antibodies were not detected. Igu (log M) Non-antipeptide IgG + propranolol 8.1 ± 0. 5 6 Values are mean ± SE and represent the effect of seven chagasic antipeptide IgG (5X iO M) and IgG devoid of antipeptide antibodies (non-antipeptide lgG) (5X107 M) that produced the maximal effect in absence or presence of atropine (5X iO M) or propranolol (5X107 M). The peptide (5X107 M) was incubated at 37#{176}C with or without IgG during 30mm and then added to the organ bath. * Significantly differentfrom basal (none) with P < 0.001. olol as a beta blocker during the 30 mm before addition of chagasic IgG, avoiding the sympathetic positive inotropic effect of chagasic antibodies.
As seen in Fig. 3 Normal IgGs were ineffective in the system studied ( Fig. 3, upper panel) . These results, which are consistent with reported studies, could be neutralized after preincubation of chagasic IgG with the peptide (5X iO M). Moreover, the affinity-purified antipeptide autoantibodies were able to inhibit in a dose-response fashion the atria dF/dt, being more potent than total IgG (Fig. 3, lower  panel) . The effect was neutralized by preincubating antipeptide antibodies with the peptide and itcould be also blocked by atropine (5X107 M) ( Table 1) . In contrast, when the IgG fraction devoid of antipeptide antibodies was assayed, the negative inotropic action disappeared, and even an increase in contractility could be observed (Table  1) . Furthermore, this positive inotropic effect was abolished by propranolol (Table 1) . This results confirm the coexistence in the sera of chagasic patients two different populations of antibodies with opposite activities on atria contractility.
To ascertain whether the biological effect of antipeptide autoantibodies and the cholinergic agonist (carbachol) were mediated by the same receptor domain, the action of carbachol upon dF/dt in the presence of threshold concentration (2X iO-M) of antipeptide autoantibody was tested. It can be seen in Fig. 4 that the preincubation of antipeptide autoantibodies during the 30 mm before addition of carbachol inhibited the dose-response curve of the agonist.
Action on intracellular cAMP and cGMP production
To evaluate the effect of chagasic antipeptide IgG on cardiac intracellular signals coupled to mAChRs, cGMP and cAMP production was measured. As shown in Table 2 , there was a significant increase in cGMP and a decrease in cAMP production by atria exposed to antipeptide cha- We also demonstrated an association in the existence of the circulating antipeptide M2 mAChR autoantibodies and the presence of dysautonomic syndrome in chagasic patients.
Moreover, the presence of these antipeptide autoantibodies detected by ELISA is stronglyassociatedwith theirabilityto alterthe myocardial behavior of the heart through mAChR activation. Taken together, these observations point to the potential role of these autoantibodies in the pathogenesis of chronic chagasic cardioneuromyopathy.
The seropositive patients without myocardial autonomic dysfunction with detectable antipeptide autoantibodies must be evaluated sequencially in order to ascertain the prognostic value of this test, indicating that these antibodies may be an early marker of heart autonomic dysfunction. 
